Literature DB >> 33255270

Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy.

Yuji Takaeko1, Masato Kajikawa2, Shinji Kishimoto1, Takayuki Yamaji1, Takahiro Harada1, Yiming Han1, Yasuki Kihara1, Eisuke Hida3, Kazuaki Chayama4, Chikara Goto5, Yoshiki Aibara6, Farina Mohamad Yusoff6, Tatsuya Maruhashi6, Ayumu Nakashima7, Yukihito Higashi2,6.   

Abstract

An elevation of serum low-density lipoprotein cholesterol (LDL-C) levels has been associated with endothelial dysfunction in statin naïve subjects. However, there is no information on endothelial function in subjects with extremely low levels of LDL-C. The purpose of the present study was to determine the relationship of LDL-C levels, especially low levels of LDL-C, with endothelial function. Endothelial function assessed by flow-mediated vasodilation (FMD) measurement and LDL-C levels were evaluated in 7120 subjects without lipid-lowering therapy. We divided the subjects into five groups by LDL-C levels: <70 mg/dL, 70-99 mg/dL, 100-119 md/dL, 120-139 mg/dL, and ≥140 mg/dL. FMD values were significantly smaller in subjects with LDL-C levels of ≥140 mg/dL than in those with LDL-C levels of 70-99 mg/dL and 100-119 mg/dL (p < 0.001 and p = 0.004, respectively). The FMD values in the LDL-C of <70 mg/dL group were not significantly different from those in the other groups. To evaluate the relationship of extremely low LDL-C levels with endothelial function, we divided the subjects with LDL-C of <70 mg/dL into those with LDL-C levels of <50 mg/dL and 50-69 mg/dL. FMD values were similar in the LDL-C <50 mg/dL group and ≥50 mg/dL group in the propensity score-matched population (p = 0.570). A significant benefit was not found in subjects with low LDL-C levels from the aspect of endothelial function.

Entities:  

Keywords:  Hypolipidemia; atherosclerosis; endothelial function; flow-mediated vasodilation; low-density cholesterol

Year:  2020        PMID: 33255270      PMCID: PMC7761134          DOI: 10.3390/jcm9123796

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  51 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

Authors:  Frederick E Dewey; Viktoria Gusarova; Richard L Dunbar; Colm O'Dushlaine; Claudia Schurmann; Omri Gottesman; Shane McCarthy; Cristopher V Van Hout; Shannon Bruse; Hayes M Dansky; Joseph B Leader; Michael F Murray; Marylyn D Ritchie; H Lester Kirchner; Lukas Habegger; Alex Lopez; John Penn; An Zhao; Weiping Shao; Neil Stahl; Andrew J Murphy; Sara Hamon; Aurelie Bouzelmat; Rick Zhang; Brad Shumel; Robert Pordy; Daniel Gipe; Gary A Herman; Wayne H H Sheu; I-Te Lee; Kae-Woei Liang; Xiuqing Guo; Jerome I Rotter; Yii-Der I Chen; William E Kraus; Svati H Shah; Scott Damrauer; Aeron Small; Daniel J Rader; Anders Berg Wulff; Børge G Nordestgaard; Anne Tybjærg-Hansen; Anita M van den Hoek; Hans M G Princen; David H Ledbetter; David J Carey; John D Overton; Jeffrey G Reid; William J Sasiela; Poulabi Banerjee; Alan R Shuldiner; Ingrid B Borecki; Tanya M Teslovich; George D Yancopoulos; Scott J Mellis; Jesper Gromada; Aris Baras
Journal:  N Engl J Med       Date:  2017-05-24       Impact factor: 91.245

3.  The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.

Authors:  Amanda J Hooper; A David Marais; Donald M Tanyanyiwa; John R Burnett
Journal:  Atherosclerosis       Date:  2006-09-20       Impact factor: 5.162

4.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.

Authors:  Kiran Musunuru; James P Pirruccello; Ron Do; Gina M Peloso; Candace Guiducci; Carrie Sougnez; Kiran V Garimella; Sheila Fisher; Justin Abreu; Andrew J Barry; Tim Fennell; Eric Banks; Lauren Ambrogio; Kristian Cibulskis; Andrew Kernytsky; Elena Gonzalez; Nicholas Rudzicz; James C Engert; Mark A DePristo; Mark J Daly; Jonathan C Cohen; Helen H Hobbs; David Altshuler; Gustav Schonfeld; Stacey B Gabriel; Pin Yue; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2010-10-13       Impact factor: 91.245

5.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Authors:  Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech
Journal:  Lancet       Date:  2015-01-09       Impact factor: 79.321

6.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

Review 7.  Interpretation of the evidence for the efficacy and safety of statin therapy.

Authors:  Rory Collins; Christina Reith; Jonathan Emberson; Jane Armitage; Colin Baigent; Lisa Blackwell; Roger Blumenthal; John Danesh; George Davey Smith; David DeMets; Stephen Evans; Malcolm Law; Stephen MacMahon; Seth Martin; Bruce Neal; Neil Poulter; David Preiss; Paul Ridker; Ian Roberts; Anthony Rodgers; Peter Sandercock; Kenneth Schulz; Peter Sever; John Simes; Liam Smeeth; Nicholas Wald; Salim Yusuf; Richard Peto
Journal:  Lancet       Date:  2016-09-08       Impact factor: 79.321

8.  Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.

Authors:  Natale Daniele Brunetti; Guglielmo Maulucci; Grazia Pia Casavecchia; Carlo Distaso; Luisa De Gennaro; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  J Interv Cardiol       Date:  2007-12       Impact factor: 2.279

9.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

10.  Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users.

Authors:  Ki-Chul Sung; Ji Hye Huh; Seungho Ryu; Jong-Young Lee; Eleonora Scorletti; Christopher D Byrne; Jang Young Kim; Dae Sung Hyun; Sang-Baek Ko
Journal:  J Clin Med       Date:  2019-10-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.